Article
Oncology
Maarten C. C. M. Hulshof, Elisabeth D. Geijsen, Tom Rozema, Vera Oppedijk, Jeroen Buijsen, Karen J. Neelis, Joost J. M. E. Nuyttens, Maurice J. C. van der Sangen, Paul M. Jeene, Jannie G. Reinders, Mark I. van Berge Henegouwen, Adriana Thano, Jeanin E. van Hooft, Hanneke W. M. van Laarhoven, Ate van der Gaast
Summary: In definitive chemoradiation for esophageal cancer, escalating radiation dose up to 61.6 Gy to the primary tumor did not significantly improve local tumor control compared to 50.4 Gy. The absence of a dose-effect was observed in both adenocarcinoma and squamous cell carcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Christian Wilhelm Langberg, Henrik Horndalsveen, Aslaug Helland, Vilde Drageset Haakensen
Summary: This study identifies factors associated with failure to start consolidation immunotherapy after chemoradiotherapy in patients with non-small cell lung cancer. Results show that patients with higher lactate dehydrogenase, worse performance status, cumulative toxicity, and higher c-reactive protein are less likely to start immunotherapy. Further research and prospective trials are needed to investigate the potential of prehabilitation and supportive treatment in optimizing treatment outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jacob S. Witt, Aleksandra Kuczmarska-Haas, Meghan Lubner, Scott B. Reeder, Steve Y. Cho, Rebecca Minter, Sharon Weber, Sean Ronnekleiv-Kelly, Daniel Abbott, Noelle LoConte, Daniel L. Mulkerin, Sam J. Lubner, Nataliya V. Uboha, Dustin Deming, Mark A. Ritter, Pranshu Mohindra, Michael F. Bassetti
Summary: The study explored the toxicity and feasibility of neoadjuvant stereotactic body radiation therapy (SBRT) with concurrent capecitabine and elective nodal irradiation (ENI) followed by surgical resection for resectable pancreatic adenocarcinoma. SBRT was safely dose escalated to 35 Gy in 5 fractions along with concurrent capecitabine and ENI, with all patients completing surgery having RO resections. Moderate treatment effect was identified in over half of the patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Katelyn M. Atkins, Tafadzwa L. Chaunzwa, Nayan Lamba, Danielle S. Bitterman, Bhupendra Rawal, Jeremy Bredfeldt, Christopher L. Williams, David E. Kozono, Elizabeth H. Baldini, Anju Nohria, Udo Hoffmann, Hugo J. W. L. Aerts, Raymond H. Mak
Summary: This cohort study explores the impact of radiation doses to cardiac substructures on major adverse cardiac events and mortality in patients with locally advanced non-small cell lung cancer. The findings suggest that dose exposure to the left anterior descending coronary artery may be an independent factor associated with adverse cardiac events and mortality, with significant interaction with baseline coronary heart disease status. Further validation and optimization of risk mitigation strategies are needed.
Article
Medicine, Research & Experimental
Zhifeng Zhao, Xiaoke Xu, Haochen Jiang, Kirk W. Foster, Zhenshan Jia, Xin Wei, Ningrong Chen, Steven R. Goldring, Mary K. Crow, Dong Wang
Summary: This study established the optimal dose-response relationships for ZSJ-0228 in treating LN in NZB/W F1 mice, showing that the most effective dose range is between 1.0 and 3.0 mg/kg/day Dex equivalent, with excellent safety profile. The resolution of proteinuria, improvement in renal histological scores, and lack of typical GC-associated side effects further support the therapeutic potential of ZSJ-0228 in LN management.
MOLECULAR PHARMACEUTICS
(2021)
Article
Oncology
Raquibul Hannan, Samer Salamekh, Neil B. Desai, Aurelie Garant, Michael R. Folkert, Daniel N. Costa, Samantha Mannala, Chul Ahn, Osama Mohamad, Aaron Laine, Dong W. Nathan Kim, Tamara Dickinson, Ganesh Raj, Rajal B. Shah, Jing Wang, Xun Jia, Hak Choy, Claus G. Roehrborn, Yair Lotan, Robert D. Timmerman
Summary: The study aimed to investigate the safety and maximum tolerated dose of multilevel MRI-guided 5-fraction SABR in patients with high-risk prostate cancer. The results showed that the dose escalation was successfully achieved without significant dose-limiting toxicities, suggesting the potential efficacy of the treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Medicine, General & Internal
Job P. van Kooten, Michelle Dietz, Niels A. D. Guchelaar, Alexandra R. M. Brandt-Kerkhof, Stijn L. W. Koolen, Jacobus W. A. Burger, Ron H. J. Mathijssen, Cornelis Verhoef, Joachim G. J. Aerts, Eva V. E. Madsen
Summary: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumor, and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the only potential curative treatment. However, most patients are not eligible for this treatment, highlighting the need for palliative options. This study aims to determine the maximum tolerable dose of intraperitoneal paclitaxel monotherapy in MPM patients and assess its safety and pharmacokinetics.
Article
Cardiac & Cardiovascular Systems
Fady I. Malik, Laura A. Robertson, Danielle R. Armas, Edward P. Robbie, Anna Osmukhina, Donghong Xu, Hanbin Li, Scott D. Solomon
Summary: This phase 1 study investigated the pharmacologically active range, safety, and tolerability of aficamten in healthy adults. The results showed that aficamten exhibited a safe profile and was well tolerated at pharmacologically active doses. The pharmacokinetics of aficamten were not affected by food intake or the presence of a specific genetic phenotype.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2022)
Article
Biology
Yan Shao, Hua Chen, Hao Wang, Aihui Feng, Ying Huang, Qing Kong, Zhiyong Xu
Summary: This study compared dosimetric and biological parameters between PET/CT-guided isotoxic SIB-IMRT plans and conventional radiotherapy plans for LA-NSCLC patients, and found that SIB can significantly increase tumor control probability without increasing the risk of complications in critical organs.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Helen Barnett, Oliver Boix, Dimitris Kontos, Thomas Jaki
Summary: This article examines the impact of employing backfilling in phase I dose-escalation studies on the estimation of the maximum tolerated dose and the duration of the study. The study finds that backfilling can increase the accuracy of selecting the maximum tolerated dose and reduce the trial duration. However, the use of backfilling comes at the cost of increased sample size.
Article
Oncology
Kathryn Banfill, Azadeh Abravan, Marcel van Herk, Fei Sun, Kevin Franks, Alan McWilliam, Corinne Faivre-Finn
Summary: This study aimed to investigate the relationship between cardiac radiation dose and death with cardiac causes following thoracic radiotherapy. The study found that an increase in cardiac radiation dose was associated with an increased cumulative incidence of death with cardiac causes in patients with cardiac comorbidities. In patients without cardiac comorbidities, mean heart dose, heart V5Gy, and heart V30Gy were associated with cardiac death.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Katelyn M. Atkins, Danielle S. Bitterman, Tafadzwa L. Chaunzwa, David E. Kozono, Elizabeth H. Baldini, Hugo J. W. L. Aerts, Balaji K. Tamarappoo, Udo Hoffmann, Anju Nohria, Raymond H. Mak
Summary: This study found that MHD is insufficient to predict LAD V15Gy with confidence, and there is discordance between MHD and LAD V15Gy. For patients with locally advanced NSCLC, isolated low LAD V15Gy can significantly reduce the risk of MACE.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Yuankai Shi, Yanqiu Zhao, Sheng Yang, Jianying Zhou, Liangming Zhang, Gongyan Chen, Jian Fang, Bo Zhu, Xingya Li, Yongqian Shu, Jianhua Shi, Rongsheng Zheng, Donglin Wang, Huiqing Yu, Jianan Huang, Zhixiang Zhuang, Gang Wu, Longzhen Zhang, Zhongliang Guo, Michael Greco, Xiao Li, Yu Zhang
Summary: Rezivertinib showed promising efficacy with a manageable safety profile in patients with EGFR T790M-mutated advanced NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Michael C. Tjong, Danielle S. Bitterman, Kristen Brantley, Anju Nohria, Udo Hoffmann, Katelyn M. Atkins, Raymond H. Mak
Summary: A prediction model for major adverse cardiac events (MACE) after radiotherapy was developed in patients with locally advanced non-small cell lung cancer (LA-NSCLC). The study found that pre-existing coronary heart disease (CHD), hypertension, and the percentage of left anterior descending (LAD) coronary artery receiving >= 15 Gy (LADV15) were important factors in predicting MACE.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Junichi Fukada, Kyohei Fukata, Naoyoshi Koike, Ryuichi Kota, Naoyuki Shigematsu
Summary: This study investigated the incidence of pericardial effusion in patients with oesophageal cancer undergoing definitive chemoradiotherapy based on the mean heart dose. The results showed that mean heart dose was a significant predictor for pericardial effusion, and the NTCP model based on MHD was comparable to the LKB model in predicting PCE. The NTCP model may provide clinically useful parameters for predicting PCE.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
John A. Vargo, Vitali Moiseenko, Jimm Grimm, Jimmy Caudell, David A. Clump, Ellen Yorke, Jinyu Xue, Yevgeniy Vinogradskiy, Eduardo G. Moros, Panayiotis Mavroidis, Sheena Jain, Issam El Naqa, Lawrence B. Marks, Dwight E. Heron
Summary: This study systematically reviewed the available literature on tumor control probability with SBRT in head and neck cancer patients, finding a dose-response relationship suggesting better local control and possibly improved overall survival with doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy. It is suggested that SBRT doses equivalent to 5-fraction doses of 40 to 50 Gy are used for retreatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Oncology
Trevor J. Royce, Panayiotis Mavroidis, Kyle Wang, Aaron D. Falchook, Nathan C. Sheets, Donald B. Fuller, Sean P. Collins, Issam El Naqa, Daniel Y. Song, George X. Ding, Alan E. Nahum, Andrew Jackson, Jimm Grimm, Ellen Yorke, Ronald C. Chen
Summary: Through a systematic review of existing literature, it was found that SBRT has potential advantages in the treatment of prostate cancer, allowing for increased biological dose escalation and shorter treatment times. Most prescription doses range from 35 to 40 Gy, delivered in 4 to 5 fractions, with excellent TCP results.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Kyle Wang, Panayiotis Mavroidis, Trevor J. Royce, Aaron D. Falchook, Sean P. Collins, Stephen Sapareto, Nathan C. Sheets, Donald B. Fuller, Issam El Naqa, Ellen Yorke, Jimm Grimm, Andrew Jackson, Ronald C. Chen
Summary: Multiple studies have shown that prostate SBRT therapy is well tolerated overall with mainly mild to moderate toxicities and very low incidence of severe toxicities. Side effects are influenced by both dosimetric and non-dosimetric factors. Further research is needed to explore tolerance doses in the future.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Dimitri G. Trembath, Eric S. Davis, Shanti Rao, Evan Bradler, Angelica F. Saada, Bentley R. Midkiff, Anna C. Snavely, Matthew G. Ewend, Frances A. Collichio, Carrie B. Lee, Georgia-Sofia Karachaliou, Fatih Ayvali, David W. Ollila, Michal T. Krauze, John M. Kirkwood, Benjamin G. Vincent, Nana Nikolaishvilli-Feinberg, Stergios J. Moschos
Summary: The presence of high tumor-infiltrating lymphocytes (TILs) in patients undergoing craniotomy for melanoma brain metastases (MBM) before 2011 may have prognostic significance. Intratumoral hemorrhage is associated with tumor volume, high expression of basic fibroblast growth factor (bFGF), and high density of CD31+alpha SMA- blood vessels.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jimm Grimm, John A. Vargo, Panayiotis Mavroidis, Vitali Moiseenko, Bahman Emami, Sheena Jain, Jimmy J. Caudell, David A. Clump, Diane C. Ling, Shiva Das, Eduardo G. Moros, Yevgeniy Vinogradskiy, Jinyu Xue, Dwight E. Heron
Summary: The study reviewed, modeled, and summarized dose-volume data for injury to carotid artery and other major vessels in SBRT/SABR head and neck reirradiation. Preliminary results suggest factors likely associated with reduced risk of bleeding events include nonconsecutive daily treatment, lower extent of circumferential tumor involvement around the vessel, and no surgical manipulation before or after SBRT.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Panayiotis Mavroidis, Kevin A. Pearlstein, Dominic H. Moon, Victoria Xu, Trevor J. Royce, Ashley A. Weiner, Colette J. Shen, Lawrence B. Marks, Bhishamjit S. Chera, Shiva K. Das, Kyle Wang
Summary: Whole brain radiation (WBRT) can cause xerostomia and dry eye. The study found that xerostomia is mainly associated with parotid dosimetric parameters, while dry eye is related to lacrimal dosimetric parameters. NTCP models were successfully created for both toxicities, helping clinicians refine dosimetric goals.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Shetal A. Patel, David E. Gerber, Allison Deal, Kathe Douglas, Chad V. Pecot, Carrie Lee, Joan Schiller, Nirav Dhruva, Jared Weiss
Summary: The study aimed to evaluate three sequences of consolidation with pembrolizumab and nab-paclitaxel in metastatic NSCLC patients, and found that these regimens were feasible and well tolerated. During the study, the majority of patients showed improvement in quality of life.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Kyle Wang, Hayley E. Malkin, Nicholas D. Patchett, Kevin A. Pearlstein, Hillary M. Heiling, Sean D. McCabe, Allison M. Deal, Panayiotis Mavroidis, Mary Oakey, Jeffrey Fenoli, Carrie B. Lee, J. Larry Klein, Brian C. Jensen, Thomas E. Stinchcombe, Lawrence B. Marks, Ashley A. Weiner
Summary: This study found that computed tomography (CT) coronary calcifications are associated with cardiac toxicity and can help ascertain baseline heart disease. The presence of coronary calcifications can identify high-risk patients and guide clinicians in taking measures before potentially cardiotoxic cancer treatments.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gregory Szalkowski, Zeynep Karakas, Mustafa Cengiz, Eric Schreiber, Shiva Das, Gozde Yazici, Gokhan Ozyigit, Panayiotis Mavroidis
Summary: The study aimed to improve clinical stereotactic body radiotherapy plans by using normal tissue complication probability objectives to minimize the risk of carotid blowout syndrome. Results showed that delineating the internal carotids and using modern treatment modalities significantly reduced the risk of CBOS, depending on the proximity of the carotid artery to the target.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2022)
Article
Oncology
Ryan T. Morse, Kaleigh Doke, Rohit G. Ganju, Sumit Sood, Panayiotis Mavroidis, Allen M. Chen
Summary: The dosimetric constraints of brachial plexus in patients undergoing SBRT for early-stage apical lung tumors have not been well-established. This study evaluated long-term experience and dosimetric correlates of outcome in the treatment of these tumors. The findings suggest the need for evidence-based dose constraints to prevent neuropathic symptoms.
PRACTICAL RADIATION ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Athanasios Tzikas, Eleftherios Lavdas, Dimitrios Kehagias, Robert Amdur, William Mendenhall, Nathan Sheets, Rebecca Green, Bhishamjit Chera, Panayiotis Mavroidis
Summary: This study aimed to determine the parameter values of three normal tissue complication probability (NTCP) models for contralateral parotid gland, contralateral submandibular gland (SMG), and contralateral salivary glands in relation to xerostomia 6-24 months after radiotherapy for oropharynx cancer. The results showed that a mean dose <22 Gy and V50 <10% for contralateral salivary glands, and a mean dose <18 Gy and V45 <10% for contralateral parotid significantly reduce the risk for radiation-induced xerostomia observed 6-24 months post-radiotherapy.
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
(2023)
Meeting Abstract
Oncology
P. Papanikolaou, G. P. Swanson, S. Stathakis, M. Fakhreddine, P. Mavroidis
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Carrie Lee, Theresa L. Werner, Allison M. Deal, Cassandra J. Krise-Confair, Tricia Adrales Bentz, Theresa M. Cummings, Stefan C. Grant, Ashley Baker Lee, Jessica Moehle, Kristie Moffett, Helen Peck, Stephen Williamson, Aleksandar Zafirovski, Kate Shaw, Janie K. Hofacker
Summary: The study collected information from 92 academic cancer research centers in North America using a survey, showing significant variations in CTO staffing, budget, trial volume, etc. These data can help cancer centers evaluate their CTO infrastructure, funding, and trial goals.
JCO ONCOLOGY PRACTICE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Eleftherios Lavdas, Maria Papaioannou, Nadia Boci, Efthimios Dardiotis, Violeta Roka, Georgios K. Sakkas, Glykeria Apostolopoulou, Lida Gogou, Panayiotis Mavroidis
Summary: This study aims to identify and categorize different artifacts in brain magnetic resonance imaging, with aliasing and ghost artifacts being the most common, while susceptibility artifacts are less frequent. The nose plays a significant role in the occurrence of these artifacts.
CURRENT PROBLEMS IN DIAGNOSTIC RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ines-Ana Jurkovic, Nikos Papanikolaou, Sotirios Stathakis, Neil Kirby, Panayiotis Mavroidis
JOURNAL OF MEDICAL PHYSICS
(2020)
Article
Oncology
Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala
Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai
Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner
Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia
Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2024)
Review
Oncology
Xiaoyong Xiang, Zhe Ji, Jing Jin
Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit
Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman
Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost
Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy
Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni
Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka
Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes
Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.
RADIOTHERAPY AND ONCOLOGY
(2024)